For a man who has come up with developing and commercializing antibody-based cancer treatment therapies, Dr. Clay Siegall remains modest in his success. Clay Seigall is a doctor by profession with a Bachelor of Science in Zoology from the University of Maryland along with a Ph.D. in genetics from the Washington University.
A scientist as well as an author, Dr. Clay started his professional career working from 1988 to 1991 at the National Cancer Institute, National Institute of health. From there he moved to the Bristol-Myers Squibb Pharmaceutical Research Institute where he worked for6 years from 1991-1997. In 1998, he co-founded Seattle Genetics, a multi-million dollar enterprise where he is the company’s President, CEO and Chairman of the Board of Directors.
Seattle Genetics is the world leading company in cancer treatment and antibody technology. It has developed a diverse portfolio of clinical and pre-clinical product targeting a variety of cancer and autoimmune indications together with coming up with an industry-leading antibody drug known as ADCETRIS (brentuximab vedotin) that received approval from the U.S. Food and Drug Administration (FDA) in 2011.
Under the leadership of Siegall, the biotechnology company has secured funding of more than $300 million from private and public finances. The company went public in 2001 which also led to the massive amounts. Also, the company has made up a large, diverse pipeline of antibody-based cancer therapies and gone into a strategic collaboration agreement with Genentech for SGN-40 valued at more than $860 million. He has also entered into several ADC collaborations including with Genentech, Med Immune, CuraGen, Bayer and Progenics that have generated more than $65 million since 2001.
Dr. Clay Siegall is on the Board of Directors of Alder Bio-pharmaceuticals, a private biotechnology company. Siegall has written more than 70 publications and had 15 patents to his name. He is a real inspiration to everyone who is thinking about making some form of change in medicine. The fact that he has struggled with Seattle Genetics for close to two decades, and did not give up on his vision also shows that he is just warming up for bigger achievements, and nothing can stop him.